Extended-Release RANCAD in the Patients With Stable Angina Pectoris

NCT ID: NCT02294942

Last Updated: 2017-04-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2016-12-31

Brief Summary

A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.

Detailed Description

Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.

Conditions

Stable Angina Pectoris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

RANCAD 500mg

RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.

Group Type: EXPERIMENTAL

RANCAD

Intervention Type: DRUG

Extended-Release RANCAD

RANCAD 1000mg

RANCAD 2 tabs (500 mg), twice daily

Group Type: EXPERIMENTAL

RANCAD

Intervention Type: DRUG

Extended-Release RANCAD

Placebo

2 tabs, twice daily

Group Type: ACTIVE_COMPARATOR

RANCAD

Intervention Type: DRUG

Extended-Release RANCAD

Interventions

RANCAD

Extended-Release RANCAD

Intervention Type: DRUG

Other Intervention Names

RNTA06

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged ≥ 20 years old

2. A minimum 3-month history of stable angina

3. Patients with diagnosis of coronary artery disease (CAD)

4. Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test

5. Patients developed exercise-induced ECG ischemiai during two qualifying exercise treadmill testsii. The difference between twoiii tests should be ≤ 20% of the longer test or ≤ 1 minute i. Exercise-induced ECG ischemia is defined as the new development of horizontal or down-sloping ST-segment depression of ≥1mm at 60-80ms after the J point; if patients with baseline ST depression at rest (<1mm), qualifying ST segment depression is defined as additional ST depression of at least 1 mm below the resting value ii. Exercise treadmill test (ETT) will be performed by Modified Bruce Protocol. iii. Two qualifying tests will be conducted 1 week apart, a 3rd ETT test will be performed ≤ 3 days when differences between previous two qualifying ETTs >20% of the longer test or >1 minute

6. Willing and able to provide a written informed consent

Exclusion Criteria

1. Factors that might compromise ECG or ETT interpretation

• Patients with resting ST-segment depression ≥ 1mm in any lead
• Left bundle-branch block
• Patients implanted with pacemaker
• Patients under Digitalis therapy

2. Patients with family history of (or congenital) long QT syndrome

3. Patients with congenital heart disease

4. Patients with uncorrected valvular heart disease

5. Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study

6. Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential* who is not using medically recognized method of contraception

*Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.

7. Patients are under any one of the following conditions:

• New York Heart Association (NYHA) Class III or Class IV congestive heart failure (CHF)
• QTc > 450 msec at screening
• Active myocarditis, pericarditis, hypertrophic cardiomyopathy

8. Use of any investigational product ≤ 4 weeks prior to screening

9. Patients with severe hepatic disease (e.g., liver cirrhosis)

10. Patients with impaired renal function (defined as serum Cr >1.5 mg/dl)

11. Patients with any condition or disease which is considered not suitable for this study by investigator

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TSH Biopharm Corporation Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Juey-Jen Hwang, M.D., Ph.D.,

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital

Locations

Far Eastern Memorial Hospital

New Taipei City, New Taipei city, Taiwan

Mackay Memorial Hospital

Taipei, Taipei City, Taiwan

Shin Kong WuHoSu Memorial Hospital

Taipei, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Taipei Veterans General Hospital

Taipei, , Taiwan

Linkou Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Countries

Taiwan

Other Identifiers

TSHRN1201

Identifier Type: -

Identifier Source: org_study_id